Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Percheron Therapeutics ( (AU:PER) ) just unveiled an update.
Percheron Therapeutics will present new preclinical data on its investigational cancer therapy HMBD-002 at the high-profile American Society of Clinical Oncology Annual Meeting in Chicago in late May to early June 2026. Acceptance at this premier oncology forum underscores growing interest in the company’s VISTA-targeting approach and may enhance its visibility among clinicians, researchers and investors as it prepares further clinical trials in 2026.
The data to be presented arises from an ongoing collaboration with leading Australian research institute QIMR Berghofer, led by immunotherapy expert Professor Sudha Rao, which is investigating the role of VISTA in multiple cancers and potential biomarkers for future studies. This collaboration-backed evidence base could help refine patient selection and trial design for HMBD-002, potentially strengthening Percheron’s competitive position in emerging immuno-oncology strategies targeting novel checkpoints.
The most recent analyst rating on (AU:PER) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Percheron Therapeutics stock, see the AU:PER Stock Forecast page.
More about Percheron Therapeutics
Percheron Therapeutics Limited is a publicly listed biotechnology company developing and commercialising novel therapies for oncology and rare diseases. Its lead program, HMBD-002, is a monoclonal antibody targeting the immune checkpoint regulator VISTA and has completed a phase I trial in advanced cancer patients, demonstrating it is generally safe and well tolerated.
Technical Sentiment Signal: Sell
Current Market Cap: A$8.37M
See more data about PER stock on TipRanks’ Stock Analysis page.